Show simple item record

dc.contributor.authorSlavin, Monica A
dc.contributor.authorChen, Yee-Chun
dc.contributor.authorCordonnier, Catherine
dc.contributor.authorCornely, Oliver A
dc.contributor.authorCuenca-Estrella, Manuel 
dc.contributor.authorDonnelly, J Peter
dc.contributor.authorGroll, Andreas H
dc.contributor.authorLortholary, Olivier
dc.contributor.authorMarty, Francisco M
dc.contributor.authorNucci, Marcio
dc.contributor.authorRex, John H
dc.contributor.authorRijnders, Bart J A
dc.contributor.authorThompson, George R
dc.contributor.authorVerweij, Paul E
dc.contributor.authorWhite, P Lewis
dc.contributor.authorHargreaves, Ruth
dc.contributor.authorHarvey, Emma
dc.contributor.authorMaertens, Johan A
dc.identifier.citationJ Antimicrob Chemother. 2021 Dec 24;77(1):16-23.es_ES
dc.description.abstractInvasive aspergillosis (IA) is an acute infection affecting patients who are immunocompromised, as a result of receiving chemotherapy for malignancy, or immunosuppressant agents for transplantation or autoimmune disease. Whilst criteria exist to define the probability of infection for clinical trials, there is little evidence in the literature or clinical guidelines on when to change antifungal treatment in patients who are receiving prophylaxis or treatment for IA. To try and address this significant gap, an advisory board of experts was convened to develop criteria for the management of IA for use in designing clinical trials, which could also be used in clinical practice. For primary treatment failure, a change in antifungal therapy should be made: (i) when mycological susceptibility testing identifies an organism from a confirmed site of infection, which is resistant to the antifungal given for primary therapy, or a resistance mutation is identified by molecular testing; (ii) at, or after, 8 days of primary antifungal treatment if there is increasing serum galactomannan, or galactomannan positivity in serum, or bronchoalveolar lavage fluid when the antigen was previously undetectable, or there is sudden clinical deterioration, or a new clearly distinct site of infection is detected; and (iii) at, or after, 15 days of primary antifungal treatment if the patient is clinically stable but with ≥2 serum galactomannan measurements persistently elevated compared with baseline or increasing, or if the original lesions on CT or other imaging, show progression by >25% in size in the context of no apparent change in immune status.es_ES
dc.description.sponsorshipF2G Ltd funded the advisory board, provided travel and accommodation costs, as well as providing an honorarium according to global, national and local regulations for the time spent at the workshop and for completing the pre- and post-meeting questionnaires. None of the authors was paid for writing or reviewing this paper.es_ES
dc.publisherOxford University Press es_ES
dc.relation.isversionofPublisher's versiones_ES
dc.titleWhen to change treatment of acute invasive aspergillosis: an expert viewpointes_ES
dc.rights.licenseAtribución-NoComercial 4.0 Internacional*
dc.contributor.funderF2G (UK)es_ES
dc.identifier.journalThe Journal of Antimicrobial Chemotherapyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial 4.0 Internacional
This item is licensed under a: Atribución-NoComercial 4.0 Internacional